Crinetics (CRNX) Q1 2026 earnings review
PALSONIFY Launch Accelerates, Payer Conversion Drives Growth
Crinetics is executing a textbook commercial launch. PALSONIFY net product revenue nearly doubled sequentially to $10.3M, shattering concerns from prior quarters about reliance on free-drug programs. The company successfully improved its reimbursed patient mix from 50% to 70% while maintaining strong volume growth (232 new enrollment forms). Operating expenses are accelerating as the company funds both its commercial infrastructure and multiple late-stage clinical trials, but a $1.3B cash fortress (bolstered by a January raise) provides a comfortable runway.
🐂 Bull Case
The transition from QuickStart (free drug) to reimbursed therapy is happening faster than anticipated. Reaching ~70% reimbursement within two quarters of launch validates the drug's strong payer reception and clinical value proposition.
Unique prescribers more than doubled to 263 total (from 125 at the end of Q4). This proves the drug is gaining broad traction in community settings, not just specialized pituitary treatment centers.
🐻 Bear Case
Total operating expenses surged to $151.1M in the quarter. Funding a global commercial launch while simultaneously running multiple pivotal trials (Acromegaly, CAH, Cushing's) guarantees heavy cash consumption for the foreseeable future.
With the commercial launch largely de-risked, investor focus will shift to atumelnant and earlier-stage assets. The ambitious trial designs (such as the novel composite endpoint for CAH) carry binary clinical risks.
⚖️ Verdict: 🟢
Bullish. Management is over-delivering on the most critical metric: successfully monetizing early patient demand. The sharp improvement in the reimbursement rate and accelerating prescriber base indicate sustainable commercial momentum.
Key Themes
Reimbursement Conversion is Accelerating
In the previous quarter, analysts voiced concerns about the high percentage (50%) of patients utilizing the QuickStart free-drug program. Management aggressively addressed this, increasing the proportion of patients on reimbursed therapy to ~70% by the end of Q1. This metric is a massive driver for near-term revenue growth and confirms that payer prior authorizations and step-edits are not materially hindering access.
Global Expansion Strategy Materializing
Crinetics is rapidly transitioning from a US-only commercial story to a global one. The European Commission approved PALSONIFY in April 2026, opening a market highly concentrated in specialty centers. Additionally, an MAA was submitted in Brazil (March 2026), and partner SKK submitted an NDA in Japan (April 2026). These regulatory milestones set the stage for stacked revenue streams outside the US.
R&D Expense Acceleration
While SG&A expenses remained stable sequentially ($50.8M vs $53.7M in Q4), Research & Development expenses are accelerating sharply, hitting $100.1M (up 18% QoQ and 31% YoY). Management attributes this to the ramp-up of ongoing Phase 3 trials and the initiation of the Phase 2/3 pediatric study for atumelnant. This aggressive R&D investment demands close monitoring to ensure clinical execution matches the spend.
Atumelnant Clinical Progression On Track
The company's next major value driver, atumelnant, is executing against its timelines. The BALANCE-CAH Phase 2/3 trial for pediatric congenital adrenal hyperplasia (CAH) initiated in January. Furthermore, the pivotal Phase 2/3 trial evaluating atumelnant for ACTH-dependent Cushing's syndrome remains on schedule to initiate in Q2 2026. Success here will validate the pipeline beyond a single asset.
Other KPIs
Stable compared to the pro forma estimate provided last quarter. The company raised $380M in net proceeds via a public equity offering in January 2026. This massive cash pile thoroughly de-risks the commercial build-out and ongoing Phase 3 trials, effectively removing near-term financing overhangs.
Net loss widened 32% YoY from -$96.8M in 25Q1, driven entirely by the step-up in R&D and SG&A expenses. Given the successful equity raise and revenue ramp, this level of cash burn is both expected and easily absorbable.
Guidance
Maintained. The midpoint of $625M implies a stable, albeit high, rate of spend. Q1 GAAP operating expenses of $151M track perfectly to a ~$604M annualized run rate, suggesting management has excellent visibility into their cost structure.
Maintained. Excludes stock-based compensation, cost of product revenue, depreciation, and amortization. First-quarter Non-GAAP OPEX came in at $120.1M, pacing exactly at the midpoint ($500M) for the full year. This reflects disciplined financial management despite the aggressive commercial and R&D expansion.
Key Questions
Steady-State Reimbursement Dynamics
You achieved a 70% reimbursed mix this quarter, a significant improvement. Do you expect this ratio to stabilize here, or is there room to compress the QuickStart (free drug) portion even further as broader formulary access is secured?
European Launch Economics
With the European Commission approval secured in April, how should we model the SG&A build-out for the EU launch? Will you commercialize directly in key markets like Germany, or rely on partnerships to manage burn?
Atumelnant R&D Cadence
R&D expenses accelerated sharply to $100M this quarter. As the Cushing's Phase 2/3 trial comes online in Q2, should we expect another sequential step-up in R&D, or are these costs largely baked into the current run rate?